Pasi Päivärinta appointed as interim CFO of Caverion
Caverion Corporation Stock exchange release 30 April 2024 at 9:00 EET
HELSINKI, April 30, 2024 /PRNewswire/ -- Pasi Päivärinta, Head of Group Business Control, has been appointed as interim CFO of Caverion Corporation as of 1 May 2024. He reports to President and CEO of Caverion Corporation Jacob Götzsche and Philip Carlsson, CFO of Assemblin Caverion Group. Päivärinta has worked in the company since 2018.
As announced earlier, Caverion Corporation and Assemblin Group AB combined on 1 April 2024 to create a leading northern European technical service and installation company, Assemblin Caverion Group.
For further information: Jacob Götzsche, President and CEO; please contact Noora Koikkalainen, Head of Marketing, Communications, IR and Sustainability, Caverion Corporation, tel. +358 50 562 6552, [email protected]
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products...
Highlights
Payment Fraud is top financial crime concern for 32% of Malaysians
Identity theft worries persist, with 37% believing they have or might have been victims
Real-time payment scams are on the rise, with 76% receiving scam...
Volvo Autonomous Solutions (V.A.S.) today unveiled Volvo's first-ever production ready autonomous truck at the ACT Expo in Las Vegas. The Volvo VNL Autonomous brings together Volvo's commercial vehicle expertise with industry-leading autonomous...
Casio Computer Co., Ltd. announced today the release of five new "Sky and Sea" models spanning five of its watch brands ? Casiotron, G-SHOCK, EDIFICE, PRO TREK, and BABY-G ? to commemorate the 50th anniversary of Casio watches. The design theme...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...
